Evidence map›Paper›PMID 24369537›Full record

ArticleBioMed research international2013

Low-cytotoxic synthetic bromorutaecarpine exhibits anti-inflammation and activation of transient receptor potential vanilloid type 1 activities.

Chi-Ming Lee, Jiun-An Gu, Tin-Gan Rau, Che-Hsiung Yang, Wei-Chi Yang, Shih-Hao Huang, Feng-Yen Lin, Chun-Mao Lin, Sheng-Tung Huang

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BioMed research international, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Rutaecarpine attenuates hypoxia-induced right ventricular remodeling in rats.Naunyn-Schmiedeberg's archives of pharmacology · 2016
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Chi-Ming LeeGraduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, No. 250, Wu-xing Street, Taipei 110, Taiwan.
Jiun-An GuInstitute of Chemical Engineering, College of Engineering, National Taipei University of Technology, Taipei, Taiwan.
Tin-Gan RauInstitute of Chemical Engineering, College of Engineering, National Taipei University of Technology, Taipei, Taiwan.
Che-Hsiung YangGraduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, No. 250, Wu-xing Street, Taipei 110, Taiwan.
Wei-Chi YangGraduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, No. 250, Wu-xing Street, Taipei 110, Taiwan.
Shih-Hao HuangDepartment of Food and Beverage Management, Taipei College of Maritime Technology, Taipei, Taiwan.
Feng-Yen LinDepartment of Internal Medicine, School of Medicine, Taipei Medical University, No. 250, Wu-xing Street, Taipei 110, Taiwan.
Chun-Mao LinDepartment of Biochemistry, College of Medicine, Taipei Medical University, No. 250, Wu-xing Street, Taipei 110, Taiwan ; Orthopedics Research Center, Taipei Medical University Hospital, Taipei, Taiwan.
Sheng-Tung HuangInstitute of Biochemical and Biomedical Engineering, College of Engineering, National Taipei University of Technology, Taipei, Taiwan.
National Taipei University of Technology · TWTaipei Medical University · TWTaipei Medical University Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rutaecarpine (RUT), the major bioactive ingredient isolated from the Chinese herb Evodia rutaecarpa, possesses a wide spectrum of biological activities, including anti-inflammation and preventing cardiovascular diseases. However, its high cytotoxicity hampers pharmaceutical development. We designed and synthesized a derivative of RUT, bromo-dimethoxyrutaecarpine (Br-RUT), which showed no cytotoxicity at 20 μM. Br-RUT suppressed nitric oxide (NO) production and tumor necrosis factor-α release in concentration-dependent (0~20 μM) manners in lipopolysaccharide (LPS)-treated RAW 264.7 macrophages; protein levels of inducible NO synthase (iNOS) and cyclooxygenase-2 induced by LPS were downregulated. Br-RUT inhibited cell migration and invasion of ovarian carcinoma A2780 cells with 0~48 h of treatment. Furthermore, Br-RUT enhanced the expression of transient receptor potential vanilloid type 1 and activated endothelial NOS in human aortic endothelial cells. These results suggest that the synthetic Br-RUT possesses very low cytotoxicity but retains its activities against inflammation and vasodilation that could be beneficial for cardiovascular disease therapeutics.

Indexed as

Anti-Inflammatory AgentsCardiovascular DiseasesDrugs, Chinese HerbalEvodiaGene Expression RegulationHumansIndole AlkaloidsInflammationMacrophagesNitric Oxide Synthase Type IIQuinazolinesQuinazolinonesTRPV Cation ChannelsAnti-Inflammatory AgentsbromorutaecarpineDrugs, Chinese HerbalIndole AlkaloidsNitric Oxide Synthase Type IINOS2 protein, humanQuinazolinesQuinazolinonesrutecarpineTRPV1 receptorTRPV Cation Channels

Identifiers

PMID24369537
PMCPMC3863474
OpenAlexW1994190786

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.